Ann: FDA Letter Requires Patient Instruction Update, page-286

Save yourself the trouble mate. Everybody here is better off discussing what BOT is doing toward successful FDA approval, what that success looks like after FDA approval, and just how far BOT may go with revenue to hand and moving forward its extensive pipeline of successful products. The Complete Response Letter from the FDA last September made it painfully clear - the FDA have NO issue with Sofdra, they just want to see better instructions and labelling. There's only one reason to be concerned with pedantic semantics - and most of us shouldn't be interested in arguing about that.

There's two reasons why BOT's SP has gone north from 12.5c over 3 weeks ago up to 15c and stayed in that vicinity:
1. The loose fruit has been shaken from the tree
2. The market values BOT's potential and places a higher value on approval next year than it did this far out from approval in 2023.